Bugworks

, CARB-X, antibiotics, AMR, Acurx, CDI, drugs, clinical trials

November 10, 2021 — India’s Bugworks Research announced Monday that it administered doses in the first human trial of its novel broad-spectrum antibiotic against multidrug-resistant Gram-negative bacteria. Bugworks is one of four CARB-X grantees conducting Phase 1 studies this year, the Bugworks press release noted. Boston University-led CARB-X has supported the company’s dual-target gyrase-topoisomerase inhibitor since…

Mentions:

The Global Antibiotic Research and Development Partnership (GARDP) announced last week that it has signed a memorandum of understanding with India’s Bugworks Research for regulatory strategies and R&D for drug-resistant antibiotic treatments for high-burden countries.

In other news, the BEAM (Biotech companies in Europe combating Antimicrobial Resistance) Alliance, which includes approximately 70 small- and medium-sized European drug developers, urged the European Union and its…

Three donor-funded companies touted successful investment offerings in recent weeks.

Affinivax announced last week that it has raised $120 million in Series B financing to advance its lead pneumococcal vaccine based on the company’s Multiple Antigen Presenting System (MAPS). The Massachusetts-based company received an initial seed and Series A equity investment from the Gates Foundation in 2014 to launch MAPS as a broad protection technology.

Meanwhile, Bugworks announced last…